SMILR and pulmonary arterial hypertension: Importantly, SMILR shRNA delivery in the MCT-induced PH rat model ameliorated PH and pulmonary vascular remodeling by targeting the Rho/ROCK/miR-141 axis [46], indicating that targeting SMILR has great potential for the treatment of PAH.